Related Experiment Video
Updated: Jun 28, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
[Design of new protocols. Role of molecular biology units?]
1Laboratoire d'oncopharmacologie, EA3836, Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice Cedex 2. gerard.milano@cal.nice.fnclcc.fr
Abstract:
The majority of current major advances in the management of main human malignancies including breast, colorectum and head and neck result from the introduction of targeted therapies. An optimal application of targeted therapy needs a knowledge for the tumoral status of the target itself. It is also interesting to dispose of biological informations resulting from the interactions between treatment and target (biological proof of the concept). These informations are at the basis of the conception of new clinical protocols in oncology. In this context the role of molecular biology units is determinant. Examples of concrete applications of this strategy will be detailled particularly for the MINDACT Trial in breast cancer and for the KRAS status in the setting of EGFR targeting therapies in advanced colorectal cancer.
Insights
Targeted therapies are advancing cancer treatment for major malignancies. Understanding tumor status and treatment interactions, guided by molecular biology, is key for developing new clinical protocols.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Major advances in treating breast, colorectal, and head and neck cancers stem from targeted therapies.
- Optimal use of targeted therapy requires knowledge of tumor target status and biological feedback from treatment-target interactions.
Purpose of the Study:
- To highlight the crucial role of molecular biology units in advancing targeted cancer therapies.
- To illustrate the application of molecular insights in designing new clinical protocols.
Main Methods:
- Review of current strategies in targeted cancer therapy.
- Detailed examples from the MINDACT Trial (breast cancer) and KRAS status assessment for EGFR inhibitors (colorectal cancer).
Main Results:
- Targeted therapies have significantly improved outcomes in major human malignancies.
- Molecular diagnostics are essential for personalized treatment selection and efficacy monitoring.
Conclusions:
- Molecular biology units are determinant in leveraging targeted therapies for improved cancer management.
- Understanding tumor biology and treatment response is fundamental for future oncology clinical trial design and personalized medicine.
Related Concept Videos
Modern Molecular Taxonomy
Applications of Molecular Taxonomy
Synthetic Biology
Golden rice
Golden rice is a genetically modified...

